WEP Clinical LTD (WEP), a specialist services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when no other treatment options are available, has partnered with TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO®, an IV treatment administered every two weeks for patients with muti-drug resistant HIV disease.

The NPP is designed to ensure that physicians in Europe and other regions around the world, where TROGARZO® is not commercially available, can request TROGARZO® on behalf of individual patients who have trouble achieving viral suppression using standard HIV regimens.

 Jas Khera, Managing Director of WEP, said:

“We are grateful to partner with TaiMed Biologics to help ensure broader access to this important HIV treatment option. The WEP Clinical team is looking forward to making TROGARZO® available to patients in Europe and rest of the world having a need for this specific HIV treatment.”

For physicians who are interested in further information on the TROGARZO® Named Patient Program, please contact: trogarzo@wepclinical.com

About WEP

At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our leading principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit  www.wepclinical.com.

About TaiMed Biologics

TaiMed Biologics was founded in 2007 and has devoted itself as a leading biopharmaceutical developer and manufacturer of innovative biologics drugs. TaiMed has developed a first-in-class anti-HIV antibody drug ibalizumab (TROGARZO®) which the US FDA and EMA approved in 2018 and 2019, respectively. Leveraging on the experience of developing TROGARZO® and other novel, long-acting anti-HIV monoclonal antibodies in the pipeline, TaiMed has also become a Contract Development and Manufacturing Organization (CDMO) offering manufacturing solutions that will enable partners to discover, develop and manufacture biologics from the bench to market. For more information, please visit www.taimedbiologics.com/.


TROGARZO® (ibalizumab-uiyk) is approved in the United States of America by the FDA as a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

TROGARZO® is a recombinant humanized monoclonal antibody that works to block HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4 and interfering with post-attachment steps required for the entry of HIV-1 virus particles into host cells and preventing the viral transmission that occurs via cell-cell fusion. TROGARZO® is administered as an intravenous infusion or intravenous push every 2 weeks.